FDA Pulmonary/Rheumatology Division Sees Management Shakeup
Deputy Director for Safety Sally Seymour will become interim director of US FDA's Pulmonary, Allergy and Rheumatology Products Division following departure of division's top two managers, Badrul Chowdhury and Lydia Gilbert McClain.
You may also be interested in...
Recent departures are 'business as usual' at the agency, Commissioner says.
US FDA's Office of New Drugs has been without a permanent director for more than a year as it undergoes a significant restructuring.
FDA will have three leadership positions vacant in the Office of Drug Evaluation II when Curtis Rosebraugh leaves at the end of the month.